Overview
CJC-1295 is a 30-amino acid synthetic analogue of endogenous GHRH (1-29) incorporating a Drug Affinity Complex (DAC) modification that enables covalent binding to serum albumin. This modification significantly extends the peptide's plasma half-life compared to native GHRH. CJC-1295 is used in research to study GHRH receptor pharmacology, albumin-binding peptide conjugation strategies, and the kinetics of sustained peptide receptor activation in in vitro cell-based models.
Compound Details
Lyophilized powder. Store at −20°C. Stable for 24 months. After preparation of working solution for laboratory assays, store at 4°C and use within 14 days.
Strictly for laboratory and in vitro research use only. Not intended, approved, or safe for human or veterinary consumption.
These compounds are sold exclusively as research reagents. No dosing, administration, or therapeutic claims are made or implied.
Purchaser assumes full responsibility for lawful research application. Buyer certifies use is for scientific study only — no personal, medical, or performance enhancement.
Products are not FDA-evaluated, not pharmaceutical-grade, and contain no sterility guarantees for human exposure.